Literature DB >> 25216634

Herb-drug interaction between irinotecan and psoralidin-containing herbs.

Xi-Shan Zhang1, Zhi-Qiang Zhao2, Zhen-Sheng Qin3, Kun Wu3, Tian-Fang Xia3, Li-Qun Pang4.   

Abstract

Herb-drug interaction strongly limits the clinical utilization of herbs and drugs. Irinotecan-induced diarrhea is closely related with the UDP-glucuronosyltransferase 1A1-catalyzed glucuronidation of SN-38 which has been widely regarded to be the toxic substance basis of irinotecan. The present study aims to determine the influence of herbal component psoralidin toward the toxicity of irinotecan. In vitro inhibition potential of psoralidin toward the glucuronidation of SN-38 was firstly investigated using human intestinal microsomes incubation system. Dose-dependent inhibition of psoralidin toward SN-38 glucuronidation was observed. Furthermore, Dixon plot showed that the intersection point was located in the second quadrant, indicating the competitive inhibition of psoralidin toward the glucuronidation of SN-38. Through the data fitting using competitive inhibition fitting equation, the inhibition kinetic parameter (K i) was calculated to be 5.8 μM. The translation of these in vitro data into the in vivo situation showed that pre-treatment with psoralidin significantly increased the toxicity of irinotecan, as indicated by the increased body weight loss and more severe colon histology damage. All these data indicated the herb-drug interaction between irinotecan and psoralidin-containing herbs.

Entities:  

Keywords:  Herb-drug interaction; Irinotecan; Psoralidin; UDP-glucuronosyltransferase (UGT) 1A1

Mesh:

Substances:

Year:  2014        PMID: 25216634     DOI: 10.1007/s13318-014-0223-8

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  13 in total

1.  Biotransformation of glucoaurantio-obtusin towards aurantio-obtusin increases the toxicity of irinotecan through increased inhibition towards SN-38 glucuronidation.

Authors:  Jian Yu; Jing-Chun Han; Ya-Jie Gao
Journal:  Phytother Res       Date:  2014-05-19       Impact factor: 5.878

Review 2.  Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral medications.

Authors:  Gregory Egan; Christine A Hughes; Margaret L Ackman
Journal:  Ann Pharmacother       Date:  2014-03-10       Impact factor: 3.154

3.  Combining bevacizumab and panitumumab with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as second-line treatment in patients with metastatic colorectal cancer.

Authors:  Hong-Liang Liang; Ai-Ping Hu; Sen-Lin Li; Ji-Yong Liu
Journal:  Med Oncol       Date:  2014-05-03       Impact factor: 3.064

4.  Kinetics of acetaminophen glucuronidation by UDP-glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen-induced hepatotoxicity.

Authors:  Abdul E Mutlib; Theunis C Goosen; Jonathan N Bauman; J Andrew Williams; Shaila Kulkarni; Seva Kostrubsky
Journal:  Chem Res Toxicol       Date:  2006-05       Impact factor: 3.739

5.  Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.

Authors:  F Saliba; R Hagipantelli; J L Misset; G Bastian; G Vassal; M Bonnay; P Herait; C Cote; M Mahjoubi; D Mignard; E Cvitkovic
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

6.  Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11).

Authors:  Shujuan Chen; Mei-Fei Yueh; Cyril Bigo; Olivier Barbier; Kepeng Wang; Michael Karin; Nghia Nguyen; Robert H Tukey
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-04       Impact factor: 11.205

7.  Cryptotanshinone and dihydrotanshinone I exhibit strong inhibition towards human liver microsome (HLM)-catalyzed propofol glucuronidation.

Authors:  Ming Cong; Cui-Min Hu; Yun-Feng Cao; Zhong-Ze Fang; Shu-Hong Tang; Jia-Rui Wang; Jun-Sheng Luo
Journal:  Fitoterapia       Date:  2013-01-17       Impact factor: 2.882

8.  The metabolic drug-drug interaction profile of Dabrafenib: in vitro investigations and quantitative extrapolation of the P450-mediated DDI risk.

Authors:  Sarah K Lawrence; Dung Nguyen; Chet Bowen; Lauren Richards-Peterson; Konstantine W Skordos
Journal:  Drug Metab Dispos       Date:  2014-04-18       Impact factor: 3.922

9.  Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes.

Authors:  Yong Liu; Jiang-Wei Zhang; Wei Li; Hong Ma; Jie Sun; Mai-Cun Deng; Ling Yang
Journal:  Toxicol Sci       Date:  2006-03-17       Impact factor: 4.849

10.  UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib.

Authors:  Judith Meza-Junco; Quincy S-C Chu; Olaf Christensen; Prabhu Rajagopalan; Soma Das; Ruslan Stefanyschyn; Michael B Sawyer
Journal:  Cancer Chemother Pharmacol       Date:  2009-08-12       Impact factor: 3.333

View more
  2 in total

1.  Inhibitory Effect of Selaginellins from Selaginella tamariscina (Beauv.) Spring against Cytochrome P450 and Uridine 5'-Diphosphoglucuronosyltransferase Isoforms on Human Liver Microsomes.

Authors:  Jae-Kyung Heo; Phi-Hung Nguyen; Won Cheol Kim; Nguyen Minh Phuc; Kwang-Hyeon Liu
Journal:  Molecules       Date:  2017-09-21       Impact factor: 4.411

2.  Inhibitory Effect of Sauchinone on UDP-Glucuronosyltransferase (UGT) 2B7 Activity.

Authors:  Byoung Hoon You; Eun Chae Gong; Young Hee Choi
Journal:  Molecules       Date:  2018-02-09       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.